Rocket Pharmaceuticals

RCKT

Market cap $404M

3.73 USD

-0.15

3.87%

At close Updated Jan 9, 4:00 PM EST

Pre-market

After hours

3.82

+0.09

2.41%

1 day

-3.87%

5 days

5.97%

1 month

11.01%

3 months

1.63%

6 months

16.56%

Year to date

7.8%

1 year

-66.52%

5 years

-93.25%

10 years

-89.51%

About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Employees: 299

Healthcare Biotechnology